

M.I. SIERRA TORRES¹, C. ALAVREZ DEL VAYO BENITO¹, A. RODRIGUEZ PÉREZ¹, M.D. TOSCANO GUZMAN¹, A. GARCIA-AVELLO FERNANDEZ-CUETO¹, J. MARTINEZ TURRIÓN¹, C. VILLANUEVA BUENO¹
¹ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, PHARMACY, SEVILLE, Spain.


BACKGROUND

- Laryngeal papillomatosis is a neoplasm of the larynx that is due to an infection by the human papillomavirus (HPV).
- It is characterized by tumors within the voice box, vocal cords or the air duct, causing breathing problems, dysphagia, stridor and sore throat.
- The treatment of choice is surgery, but some patients require adjuvant treatment, such as cidofovir or alpha interferon.


PURPOSE

- To describe the efficacy and safety of the treatment with interferon alpha 2A in laryngeal papillomatosis.

MATERIAL AND METHOD



RESULTS



CONCLUSIONS

It seems that interferon alpha 2-A is an effective and relatively safe treatment, as described adverse effects have not been a great damage to the patient in the treatment of laryngeal papillomatosis. It is necessary to monitor the use of interferon alfa because it has been only used for 5 months in one patient, although the results are encouraging to be considered as a new therapeutic alternative to these patients.